ES2162871T3 - Derivados oxindoles sustituidos en la posicion 3 de accion biologica, utiles como agentes anti-angiogenicos. - Google Patents

Derivados oxindoles sustituidos en la posicion 3 de accion biologica, utiles como agentes anti-angiogenicos.

Info

Publication number
ES2162871T3
ES2162871T3 ES94931583T ES94931583T ES2162871T3 ES 2162871 T3 ES2162871 T3 ES 2162871T3 ES 94931583 T ES94931583 T ES 94931583T ES 94931583 T ES94931583 T ES 94931583T ES 2162871 T3 ES2162871 T3 ES 2162871T3
Authority
ES
Spain
Prior art keywords
hydrogen
alkyl
halogen
tetralin
isoquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94931583T
Other languages
English (en)
Inventor
Franco Buzzetti
Antonio Longo
Maria Gabriella Brasca
Fabrizio Orzi
Angelo Crugnola
Dario Ballinari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Application granted granted Critical
Publication of ES2162871T3 publication Critical patent/ES2162871T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE PRESENTA EL NUEVO USO DE UN COMPUESTO DE LA FORMULA (I) EN LA QUE Y ES UN ANILLO BICICLICO SELECCIONADO DEL NAFTALENO, TETRALINA, QUINOLINA, ISOQUINOLINA E INDOL; N ES CERO O UN ENTERO DE 1 A 3; R{SUB,1} ES HIDROGENO, ALQUILO C{SUB,1}-C{SUB,6} O ALCANOILO C{SUB,2}-C{SUB,6}; R{SUB,2} ES HIDROGENO, HALOGENO, ALQUILO C{SUB,1}-C{SUB,6}, CIANO, CARBOXI, NITRO O NHR, EN DONDE R ES HIDROGENO O ALQUILO C{SUB,1}-C{SUB,6}; R{SUB,3} ES HIDROGENO O ALQUILO C{SUB,1}-C{SUB,6}; R{SUB,4} ES HIDROGENO, HIDROXI, ALCOXI C{SUB,1}-C{SUB,6}, ALCANOILOXI C{SUB,2}-C{SUB,6}, CARBOXI, NITRO O NHR, EN DONDE R ES COMO SE HA DEFINIDO ARRIBA; R{SUB,5}ES HIDROGENO, ALQUILO C1{SUB,1}-C{SUB,6} O HALOGENO; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; Y EN LA QUE CUANDO Y ES NAFTALENO N ES CERO O UN ENTERO DE 1 A 3, MIENTRAS QUE CUANDO Y ES TETRALINA, QUINOLINA, ISOQUINOLINA O INDOL N ES CERO, 1 O 2; Y EN LA QUE CUANDO EL ANILLO BICICLICLO Y ES NAFTALENO, QUINOLINA, ISOQUINOLINA O INDOL, CADA UNO DE LOS SUSTITUYENTESOR{SUB,2}, R{SUB,2} Y OXINDOLILIDENO PUEDEN ESTAR INDEPENDIENTEMENTE EN CUALQUIERA DE LA UNIDADES ARILO O HETEROARILO DE DICHO ANILLO BICICLICO, MIENTRAS QUE SOLO LA UNIDAD DE BENCENO SE SUSTITUYE CUANDO Y ES TETRALINA; Y EN LA QUE CUANDO Y ES NAFTALENO, TETRALINA, QUINOLINA O ISOQUINOLINA, R{SUB,2} ES HIDROGENO, HALOGENO, CIANO O ALQUILO C{SUB,1}C{SUB,6} Y R{SUB,3}, R{SUB,4} Y R{SUB,5} SON HIDROGENO; MIENTRAS QUE CUANDO Y ES INDOL, R{SUB,2} ES HIDROGENO, HALOGENO, ALQUILO C{SUB,1}-C{SUB,6}, CIANO, CARBOXI, NITRO O -NHR, EN DONDE R ES COMO SE HA DEFINIDO ARRIBA, R{SUB,3} ES HIDROGENO O ALQUILO C{SUB,1}-C{SUB,6,}, R{SUB,4} ES HIDROGENO, HIDROXI, ALCOXI C{SUB,1}-C{SUB,6}, ALCANOILOXI C{SUB,2}-C{SUB,6}, CARBOXI, NITRO O -NHR, EN DONDE R ES COMO SE HA DEFINIDO ARRIBA Y R{SUB,5} ES HIDROGENO, HALOGENO O ALQUILO C{SUB,1}-C{SUB,6}; COMO AGENTE ANTIANGIOGENICO.
ES94931583T 1993-12-22 1994-11-08 Derivados oxindoles sustituidos en la posicion 3 de accion biologica, utiles como agentes anti-angiogenicos. Expired - Lifetime ES2162871T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939326136A GB9326136D0 (en) 1993-12-22 1993-12-22 Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents

Publications (1)

Publication Number Publication Date
ES2162871T3 true ES2162871T3 (es) 2002-01-16

Family

ID=10746990

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94931583T Expired - Lifetime ES2162871T3 (es) 1993-12-22 1994-11-08 Derivados oxindoles sustituidos en la posicion 3 de accion biologica, utiles como agentes anti-angiogenicos.

Country Status (17)

Country Link
US (1) US5576330A (es)
EP (1) EP0684820B1 (es)
JP (1) JPH08507089A (es)
KR (1) KR960700707A (es)
AT (1) ATE204168T1 (es)
AU (1) AU676958B2 (es)
CA (1) CA2155098A1 (es)
DE (1) DE69427962T2 (es)
ES (1) ES2162871T3 (es)
GB (1) GB9326136D0 (es)
HU (1) HUT73176A (es)
IL (1) IL112010A (es)
NO (1) NO953146D0 (es)
PL (1) PL310379A1 (es)
TW (1) TW273510B (es)
WO (1) WO1995017181A1 (es)
ZA (1) ZA9410204B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9610964D0 (en) * 1996-05-24 1996-07-31 Pharmacia & Upjohn Spa Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9611797D0 (en) * 1996-06-06 1996-08-07 Pharmacia Spa Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
AU7622698A (en) * 1996-12-05 1998-06-29 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
AU8918898A (en) 1997-08-25 1999-03-16 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibi tors
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
AU771224B2 (en) 1998-07-13 2004-03-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
US6630488B1 (en) 1998-09-21 2003-10-07 Biochem Pharma, Inc. Quinolizinones as integrin inhibitors
WO2000035921A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
BR9916327A (pt) 1998-12-17 2001-09-18 Hoffmann La Roche Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
CN1136217C (zh) 1998-12-17 2004-01-28 霍夫曼-拉罗奇有限公司 作为jnk蛋白质激酶抑制剂的4-芳基羟吲哚
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
AR034118A1 (es) 2000-02-15 2004-02-04 Sugen Inc Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
IL152682A0 (en) * 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
AU2001268154A1 (en) 2000-06-02 2001-12-17 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2002096361A2 (en) 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1572078A4 (en) * 2002-03-08 2006-08-09 Univ Emory NEW CURCUMINOID FACTOR VIIa CONSTRUCTS AS MEANS OF SUPPRESSING TUMOR GROWTH AND ANGIOGENESIS
US7572442B2 (en) 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Selected antibody compositions for binding to aminophospholipids
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
ES2410587T3 (es) 2004-01-22 2013-07-02 University Of Miami Formulaciones tópicas de coenzima Q10 y métodos de uso
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
EP2633864A1 (en) 2008-07-25 2013-09-04 The Regents of the University of Colorado Clip inhibitors and methods of modulating immune function
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CN102115469A (zh) * 2011-03-21 2011-07-06 浙江大学 吲哚啉-2-酮类衍生物的制备和用途
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
EP2837626A1 (en) * 2013-08-16 2015-02-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Indolinone derivatives as GRK5 modulators
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
WO2018145109A1 (en) 2017-02-06 2018-08-09 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9000950D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa New arylvinylamide derivatives and process for their preparation
GB9000939D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa Improvement in the total synthesis of erbstatin analogs
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
CA2108889A1 (en) * 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
CA2140440A1 (en) * 1992-08-06 1994-02-17 Ellen M. Dobrusin 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation

Also Published As

Publication number Publication date
AU8061294A (en) 1995-07-10
CA2155098A1 (en) 1995-06-29
HU9502761D0 (en) 1995-11-28
WO1995017181A1 (en) 1995-06-29
NO953146L (no) 1995-08-10
JPH08507089A (ja) 1996-07-30
EP0684820B1 (en) 2001-08-16
US5576330A (en) 1996-11-19
HUT73176A (en) 1996-06-28
ATE204168T1 (de) 2001-09-15
IL112010A (en) 1998-10-30
TW273510B (es) 1996-04-01
ZA9410204B (en) 1995-11-10
AU676958B2 (en) 1997-03-27
GB9326136D0 (en) 1994-02-23
DE69427962D1 (de) 2001-09-20
EP0684820A1 (en) 1995-12-06
IL112010A0 (en) 1995-03-15
DE69427962T2 (de) 2002-04-04
PL310379A1 (en) 1995-12-11
NO953146D0 (no) 1995-08-10
KR960700707A (ko) 1996-02-24

Similar Documents

Publication Publication Date Title
NO953146L (no) Biologisk aktive 3-substituerte oksindolderivater som er nyttige som antiangiogeniske midler
CA2053253A1 (en) New aryl-and heteroarylethenylene derivatives and process for their preparation
DK151808C (da) Analogifremgangsmaade til fremstilling af oxadiazolylimidazo-oe1,4aa-benzodiazepinderivater
GR3036579T3 (en) 5-arylindole derivatives and their use as serotonin (5-ht 1?) agonists.
DE69528229D1 (en) N-substituierte beta-aryl und beta-heteroaryl-alpha-cyamoacrylamidderivate als tyrosine kinase inhibitoren
HUP9902111A2 (hu) Biciklusos aminok és N-oxidjaik, intermedierjeik, előállításuk és alkalmazásuk, a vegyületeket tartalmazó inszekticid, akaricid és nematocid készítmények
ATE228364T1 (de) Indolalkaloide als antientzündliche wirkstoffe
PT96757A (pt) Processo de preparacao de derivados de indolo e de composicoes farmaceuticas
MX9204194A (es) Los compuestos de 1,2,4-oxadiazolil-fenoxialquilisoxazolas y su uso como agentes antivirales
AU3773397A (en) Method for preparing halogenated 2-amino or 2-acetamido trifluoromethylbenzene derivatives
DK316986A (da) Kemiske forbindelser, som er phosphodiesterase type iii inhibitorer
DE3362723D1 (en) Pyrido-triazoloquinazolines, their preparation and use
ES8102144A2 (es) Procedimiento para la preparacion de derivados de la isoqui-noleina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 684820

Country of ref document: ES